Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Diabetic Neuropathy, Painful
Interventions
DEVICE

Frequency Modulated Neural Stimulation (FREMS) (Aptiva)

FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.

DEVICE

sham treatment (Aptiva)

The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.

Trial Locations (6)

20132

San Raffaele Hospital & Scientific Institute, Milan

35143

University of Padua, Padua

40225

Heinrich Heine University, Düsseldorf

Unknown

Paris-Nord University, Bondy

06100

University of Perugia, Perugia

00133

Tor Vergata University, Rome

All Listed Sponsors
lead

Lorenz Biotech S.p.A.

INDUSTRY

NCT01628627 - Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy | Biotech Hunter | Biotech Hunter